Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11837082 | 0.91 | L3MBTL1 (0.59) | L3MBTL1TSHRALOX15HSD17B10POLB | |
| SCHEMBL3753324 | 0.82 | L3MBTL1 (0.64) | L3MBTL1TSHRALOX15HSD17B10POLB | |
| SCHEMBL3404224 | 0.81 | L3MBTL1 (0.63) | L3MBTL1TSHRALOX15HSD17B10POLB | |
| SCHEMBL8642977 | 0.81 | — | — | |
| SCHEMBL10972781 | 0.81 | ALDH1A1 (0.50) | L3MBTL1TSHRALOX15HSD17B10POLB | |
| SCHEMBL423999 | 0.80 | L3MBTL1 (0.61) | L3MBTL1TSHRALOX15HSD17B10POLB | |
| SCHEMBL13522679 | 0.80 | L3MBTL1 (0.61) | L3MBTL1TSHRALOX15HSD17B10POLB | |
| SCHEMBL2262931 | 0.80 | L3MBTL1 (0.61) | L3MBTL1TSHRALOX15HSD17B10POLB | |
| SCHEMBL5807658 | 0.78 | L3MBTL1 (0.59) | L3MBTL1TSHRALOX15HSD17B10POLB | |
| SCHEMBL78389 | 0.78 | L3MBTL1 (0.59) | L3MBTL1TSHRALOX15HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109456704-B | Metal Chemical Mechanical Planarization (CMP) compositions and methods thereof | 弗萨姆材料美国有限责任公司 | 2021-08-27 | — | — | CN | claimed |
| US-10920106-B2 | Metal chemical mechanical planarization (CMP) composition and methods therefore | VERSUM MATERIALS US, LLC (US) | 2021-02-16 | — | — | US | claimed |
| CN-107624113-B | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-10-23 | — | — | CN | claimed |
| US-20200032107-A1 | Metal Chemical Mechanical Planarization (CMP) Composition And Methods Therefore | VERSUM MATERIALS US, LLC (US) | 2020-01-30 | — | — | US | claimed |
| US-10465096-B2 | Metal chemical mechanical planarization (CMP) composition and methods therefore | VERSUM MATERIALS US, LLC (US) | 2019-11-05 | — | — | US | claimed |
| EP-3292120-B1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | claimed |
| CN-109456704-A | Metal chemical mechanical planarization (CMP) compositions and methods thereof | 弗萨姆材料美国有限责任公司 | 2019-03-12 | — | — | CN | claimed |
| EP-3292120-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | H. Hoffnabb-La Roche Ag (CH) | 2018-03-14 | — | — | EP | claimed |
| US-9845322-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-12-19 | — | — | US | claimed |
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | claimed |
| EP-0454501-B1 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | SANKYO CO (JP) | 2001-09-05 | — | — | EP | claimed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | claimed |
| US-5958929-A | CONGESTIVE HEART FAILURE; HYPOTENSIVE AGENTS | SANOFI (FR) | 1999-09-28 | — | — | US | claimed |
| EP-0888351-A1 | PYRIMIDO 5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1999-01-07 | — | — | EP | claimed |
| US-5821240-A | ENZYME INHIBITORS, SIGNAL INHIBITORS FOR ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS AND HORMONE INHIBITORS | DR. KARL THOMAE GMBH (DE) | 1998-10-13 | — | — | US | claimed |
| EP-0839812-A1 | Preparation of benzylthiazolidine derivatives | Sankyo Company Limited (JP) | 1998-05-06 | — | — | EP | claimed |
| WO-1997032880-A1 | PYRIMIDO[5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | claimed |
| WO-1996028448-A1 | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | claimed |
| US-5489693-A | ANTICOAGULANTS | DR. KARK THOMAE, GMBH (DE) | 1996-02-06 | — | — | US | claimed |
| EP-0454501-A2 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | Sankyo Company Limited (JP) | 1991-10-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | TPMT, DPYD, HAVCR2 | L3MBTL1 2774/4885TSHR 1669/4885ALOX15 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.